Final overall survival analysis of the HER2CLIMB RCT: Tucatinib vs. placebo added to Trastuzumab and Capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases.

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link to abstract – $ for full-text)

Original Study: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer